| ［1］Tonelli M, Lloyd A, Clement F, et al. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis［J］. CMAJ, 2011, 183(16): E1189-1202.
［2］Joy TR, Hegele RA. Narrative review: statin-related myopathy［J］. Ann Intern Med, 2009, 150(12): 858-868.
［3］Khan FY. Rhabdomyolysis: a review of the literature［J］. Neth J Med, 2009, 67(9): 272-283.
［4］Torres PA, Helmstetter JA, Kaye AM, et al. Rhabdomyolysis: pathogenesis, diagnosis, and treatment［J］. Ochsner J, 2015, 15(1):58-69.
［5］Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipidlowering drugs［J］. JAMA, 2004, 292: 2585-2590.
［6］江岳鑫, 娄莹, 刘玉清, 等. 他汀类药物致160 例肌病相关不良反应的临床分析［J］. 中华高血压杂志, 2014, 42: (11): 905-909.
［7］黄惠明. 20082013年他汀类药物致横纹肌溶解症文献分析［J］. 中国药物应用与监测, 2014, 11(2): 107-110.
［8］Albayda J, ChristopherStine L. Identifying statinassociated autoimmue necrotizing myopathy ［J］. Cleve Clin J Med, 2014, 81:736-741.
［9］Vrablik M, Zlatohlavek L, Stulc T, et al. Statin-associated myopathy: from genetic predisposition to clinical management［J］. PhysiolRes, 2014, 63Suppl3: S327-334.
［10］Abramson JD, Rosenberg HG, Jewel N, et al. Should people at low risk of cardiovascular disease take a statin［J］? BMJ, 2013, 347: f6123.
［11］刘建平, 邢建民. 循证的药品不良反应评价方法［J］. 中国药物警戒, 2010, 7(1): 12-15.
［12］Ramkumar S , Raghunath A , Raghunath S . Statin Therapy: Review of Safety and Potential Side Effects［J］. Acta Cardiol Sin, 2016, 32 (6): 631-639.
［13］HuertaAlardn AL, Varon J, Marik PE. Bench-to-bedside review: Rhabdomyolysisan overview for clinicians［J］. Crit Care, 2005, 9(2):158-169.
［14］Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with highdosage statin therapy in hyperlipidemic patientsthe PRIMO study［J］. Cardiovasc Drugs Ther, 2005, 19(6): 403-414.
［15］Frydrychowicz C, Pasieka B, Pierer M, et al. Colchicine triggered severe rhabdomyolysis after long-term low-dose simvastatin therapy: a case report［J］. J Med Case Rep, 2017, 11(1):8-13.
［16］Duncan SJ, Howden CW. Proton Pump Inhibitors and Risk of Rhabdomyolysis［J］. Drug Saf, 2017, 40(1): 61-64.
［17］Li DQ, Kim R, McArthur E, et al. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4［J］. CMAJ, 2015, 187(3):174-180.
［18］Hirota T, Ieiri I. Drug-drug interactions that interfere with statin metabolism［J］. Expert Opin Drug Metab Toxicol, 2015, 10: 1-13.
［19］Blaier O, Lishner M, Elis A. Managing statin-induced muscle toxicity in a lipid clinic［J］. J Clin Pharm Ther, 2011, 36(3):336-341.
［20］Simons JE, Holbrook AM, Don-Wauchope AC. Successful reintroduction of statin therapy after statin-associated rhabdomyolysis［J］. J Clin Lipidol, 2015, 9(4):594-596.
［21］熊贤兵, 李刚, 罗文艳, 等. 1例辛伐他汀联用罗红霉素致横纹肌溶解患者的药学监护［J］. 中南药学, 2015, 13(6): 660-662.
［22］中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南（2016年修订版）［J］. 中国循环杂志, 2016, 31(10): 937-953. |
